US Judge Dismisses Gautam Adani Criminal Charges 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Airbus Joins Air India A320 Altitude Drop Probe 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
OpenAI Restricts Astra AI Over Cyberattack Risks 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Danish biotechnology leader Genmab A/S (CSE: GMAB) is reportedly in advanced negotiations to acquire Merus NV (NASDAQ: MRUS), a Dutch biotech company specializing in innovative cancer therapies. According to Bloomberg, people familiar with the matter indicated that the potential deal could be announced within days.
If completed, this acquisition would mark the largest deal in Genmab’s history, underscoring the company’s commitment to strengthening its oncology pipeline. Genmab, based in Copenhagen, currently has a market capitalization of about $18.5 billion, while Merus is valued at approximately $5.2 billion on Nasdaq.
Merus has recently attracted strong interest from several major pharmaceutical companies due to the success of its experimental cancer drug, petosemtamab. In May, the company reported encouraging clinical trial data showing that petosemtamab significantly shrank tumors in patients with head-and-neck cancer. When paired with Merck’s (NYSE: MRK) blockbuster immunotherapy Keytruda, the treatment demonstrated greater effectiveness than existing standard therapies, boosting investor confidence and propelling Merus shares higher.
For Genmab, which has built a strong reputation for developing antibody-based treatments, acquiring Merus could provide a strategic edge in the competitive immuno-oncology market. The deal would expand its drug portfolio, enhance collaboration opportunities with pharmaceutical giants, and accelerate the development of next-generation therapies targeting some of the most challenging cancers.
Industry analysts note that such a move reflects a broader trend in the biotech sector, where established players are aggressively pursuing mergers and acquisitions to secure breakthrough technologies and promising drug candidates. If finalized, this transaction would not only reshape Genmab’s growth trajectory but also reinforce its position as a global oncology powerhouse.
The coming days will be crucial as discussions progress, with investors closely watching for official confirmation of what could become a transformational deal in the biotech industry.
